Dr. Abasi Ene-Obong is the Founder of 54gene. He is a seasoned business leader with extensive experience in the US, UK and Nigerian healthcare industries. Among other notable mentions, Dr. Ene-Obong has been recognised as one of Africa’s young innovators, one of Fortune’s 40 under 40 most influential people in healthcare and is a Bloomberg Catalyst in recognition of his contributions towards accelerating solutions to global health problems. 54gene is a health technology company equalizing precision medicine for Africans and the global population through innovative scientific research, advanced molecular diagnostics and clinical studies. The company is working to ensure that Africa, a genetically diverse population, is adequately represented in drug discovery and other clinical research.
Track Chair: - Courtney McFall, UCSF
- Ben Rubin, UCSF
Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support.